European Patent granted for Colli-Pee

You are here

European Patent Colli-Pee

Wijnegem, Belgium, November 30 2018:

Novosanis announced today that the European Patent Office (EPO) has granted the company's patent application in Europe [Patent Number: 2892434], for Colli-Pee a urine capturing device that enables standardized collection of first-void urine (first 20ml of urine) by both genders without the need to interrupt urine flow.  

“Getting the European patent granted for our Colli-Pee device is a major achievement for our company and confirms the innovative and unique aspects of our device. First-void urine collected with Colli-Pee is highly suitable for the non-invasive detection of sexually transmitted infections such as HPV as well as early detection and monitoring of (urologic) cancer biomarkers.  We are excited for the new opportunities this brings for Colli-Pee in the world of diagnostics and healthcare in Europe,” explains Koen Beyers, CTO Novosanis.

 

For more information, please contact:

Koen Beyers, CTO Novosanis

Koen.beyers@novosanis.com

+3234855016

 

About Novosanis

Novosanis is an innovative developer and producer of medical devices adding value to the accuracy of diagnostics tests as well as drug delivery in the field of prevention, detection and treatment of infectious diseases and oncology.

Novosanis is a Belgian privately held company endorsed on multiple occasions nationally and internationally for its solutions and is ISO13485 certified.

Novosanis prospers in user-friendly and clever medical devices meeting all regulatory and quality requirements for self-sampling and drug delivery solutions that improve accuracy and standardization while making handling easier, more consistent and more comfortable for the user.

The company has two device platforms in portfolio:

  • VAX-ID™ is a patented and proven platform of injection devices suited for accurate drug delivery of e.g. therapeutic, prophylactic and allergy vaccines in the dermal layer of the skin and
  • Colli-Pee™ is a patented sampling device suited for standardized and guaranteed collection of first-void urine (first 20ml of the urine flow) allowing improved detection of infectious diseases as well as early stage cancer. Colli-Pee™ is in a commercial stage. It is CE-marked and FDA listed.

For more information, please visit:  www.novosanis.com